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Erica D. Warlick, Adina Cioc, Todd DeFor, Michelle Dolan, Daniel WeisdorfAllogeneic stemcell transplantation is the only known curative therapy formyelodsyplastic syndromes (MDS).
We present the transplant outcomes for 84 adult MDS patients, median age 50 (18-69 years), undergoing al-
logeneic hematopoietic stem cell transplantation (HSCT) at the University of Minnesota between 1995 and
2007. By WHO criteria 35 (42%) had refractory anemia with excess blasts (RAEB-1 or 2), 23 (27%) had re-
fractory cytopenia with multilineage dysplasia (RCMD) or RCMD and ringed sideroblasts (RCMD-RS), and
the remaining 26 (31%) had refractory anemia (RA), myelodysplastic syndrome-unclassifiable (MDS-U),
chronic myelomonocytic leukemia (CMML), myelodysplastic/myeloproliferative disease (MDS/MPD), or
myelodysplastic syndrome-not otherwise specified (MDS-NOS). Graft source was related in 47 (56%), unre-
lated donor (URD) marrow in 11 (13%), and unrelated cord blood (UCB) in 26 (31%). The conditioning reg-
imen included total body irradiation (TBI) in 94% of transplantations; 52 (62%) myeloablative (MA) and 32
(38%) nonmyeloablative (NMA) regimens. Cumulative incidence of neutrophil engraftment by day142, acute
graft-versus-host disease (aGVHD) by day 1100, and chronic GVHD (cGVHD) by 1 year were 88% (80%-
96%, 95% confidence interval [CI]), 43% (36%-50%, 95% CI), and 15% (10%-20%, 95% CI), respectively.
One-year treatment-related mortality (TRM), relapse, disease-free survival (DFS), and overall survival
(OS) were 39% (28%-50%, 95% CI), 23% (12%-32%, 95% CI), 38% (28%-48%, 95% CI), and 48% (38%-58%,
95% CI) respectively. Cumulative incidence of relapse at 1 year in patients with pre-HCT complete remission
(CR) or\5% blasts was improved at 18% (8%-28%, 95% CI) compared to 35% (16%-54%, 95% CI) in patients
with 5%-20% blasts (P5 .07). Additionally, with MA conditioning, the incidence of relapse at 1 year trended
lower at 16% (6%-26%, 95%CI) versus 35% (18%-52%, 95%CI) in NMA (P5.06), and a statistically significant
decrease in relapse was noted in patients entering HCTwith CR or\5% blasts with an incidence of 9% (0%-
18%, 95%CI) (MA) versus 31% (11%-51%, 95%CI) (NMA) (P5 0.04). For those patients with$5% blasts, MA
conditioning did not significantly decrease relapse rates. One-year TRM was similar between MA and NMA
conditioning. For patients entering transplant in CR orwith\5% blasts, prior treatment to reach this level did
not impact rates of relapse or transplant-related mortality when all patients were analyzed; however, when
broken down by conditioning intensity, there was a trend toward improved DFS in those NMA patients
who were pretreated. Finally, 1-year DFS was similar using related donor peripheral blood stem cell
(PBSC)/marrow, URD marrow, or UCB grafts. These data suggest that (1) blast percentage\5% at HSCT
is the major predictor of improved DFS and relapse and prior treatment to reach this disease status may
have value in leading to improved DFS; (2) MA conditioning is associated with lower relapse risk, particularly
in patients with CR or\5% blasts, but is not able to overcome increased disease burden; (3) NMA condition-
ing yields equivalent TRM, DFS, and OS, and is reasonable in patients unsuited for MA conditioning; (4) the
donor sources tested (PBSC, bone marrow [BM], or UCB) yielded similar outcomes.
Biol Blood Marrow Transplant 15: 30-38 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: MDS, Myelodysplastic syndromes, Allogeneic transplantBlood and Marrow Transplant Program, Departments of
ine and Laboratory Medicine and Pathology, University
nnesota, Minneapolis, Minnesota.
isclosure: See Acknowledgments on page 37.
dence and reprint requests: Erica D.Warlick, MD, Blood
arrow Transplant Program, Department of Medicine,
rsity of Minnesota, 420 Delaware Street SE, MMC 480,
eapolis, MN 55455 (e-mail: ewarlick@umn.edu).
uly 15, 2008; accepted October 9, 2008
/09/151-0001$36.00/0
6/j.bbmt.2008.10.012INTRODUCTION
Myelodysplastic syndromes (MDS) are a complex
and heterogeneous group of clonal hematopoietic
stem cell disorders for which the only known cure is
allogeneic hematopoietic stem cell transplantation
(HSCT). Despite the curative potential of HSCT,
many unanswered questions regarding HSCT in
MDS remain: does the timing of transplant, disease sta-
tus at transplant, pretransplant therapy, conditioning
Biol Blood Marrow Transplant 15:30-38, 2009 31Allogeneic SCT for Adults with MDSintensity, or stem cell source alter the long-term out-
comes of patients who have undergone allogeneic
HCT?
The International Prognostic Scoring System
(IPSS) is the most validated prognostic scoring system
for MDS, providing information that assists clinicians
inmaking treatment decisions and timing of transplan-
tation. Early studies suggested that patients with MDS
had the best outcomes if they were transplanted early
in the course of their disease, particularly in those
patients with low-risk disease. Although improved
disease-free survival (DFS) and overall survival (OS)
have been reported in this subset of lower risk patients
[1], given the treatment-related morbidity and mortal-
ity (TRM) associated with transplants, some clinicians
suggest that the risks of TRM and morbidity outweigh
the benefits in this low-risk group of patients. Addi-
tionally, data from Kuendgen and Cutler and their as-
sociates [2,3] suggest that low-risk, younger patients
can often have an extended period of time before sig-
nificant disease progression and early transplantation
in lower risk MDS (low, INT-1) actually leads to
life-years lost, thus recommending upfront transplan-
tation for patients with INT-2 or high-risk disease and
delayed transplant for low-risk and INT-1 patients un-
til disease progression but prior to leukemic transfor-
mation [2,3].
Because the timing and choice of transplant tech-
niques to produce the best outcome remain uncertain,
we reviewed the outcomes of 84 consecutive patients
who underwentHSCT forMDS in light of their disease
status, conditioning regimen intensity, and donor type.MATERIALS AND METHODS
Patients
We present a retrospective analysis of 84 consecu-
tive adult MDS patients who underwent allogeneic
HSCT at the University of Minnesota between Janu-
ary 1995 andMay 2007. Patients withMDSwere iden-
tified through our institutional Bone Marrow
Transplant database. All donor types (related (56%),
unrelated (13%), and cord blood (31%) transplants)
were included in analysis. The median length of
follow-up among surviving patients was 2.4 years.Disease Characteristics and Classification
Because of advances in the understanding and clas-
sification of patients with MDS over the years, we
rereviewed in detail both the medical record and all
available hematopathologic slides. The data collected
included both diagnostic MDS WHO classification
and the ‘‘pre-BMT’’ WHO classification equivalent
reflecting therapy and/or disease evolution, percent
of blasts in the bone marrow, the number of cytope-nias, and cytogenetic results; the IPSS score was then
calculated from this data. A hematopathologist (A.C.)
reviewed all available cases including the diagnostic
and pretransplant material in those cases previously
classified using FAB nomenclature, and in more recent
cases classified by the WHO recommendations as
needed to resolve ambiguous classification. Six cases
(7%) had no original diagnostic material available for
review and WHO classification was based on outside
pathology reports. All 84 patients were reclassified ac-
cording to current WHO recommendations: refrac-
tory anemia (RA), refractory anemia with ringed
sideroblasts (RARS), refractory cytopenias with multi-
lineage dysplasia (RCMD, including RCMD-RS),
refractory anemia with excess blasts (RAEB-1 and
RAEB-2), acutemyelogenous leukemia (AML),myelo-
dysplastic/myeloproliferative disease (MDS/MPD)
unclassifiable, myelodysplastic syndrome-unclassifi-
able (MDS-U), chronic myelomonocytic leukemia
(CMML), andMDSnot otherwise specified (NOS) [4].
Calculation of IPSS Score
The IPSS score was calculated for patients both at
diagnosis and pretransplant time points using cytoge-
netic data, number of cytopenias, and bone marrow
blast percentage [5]. For those patients with incom-
plete data, the IPSS was calculated only if the IPSS
score was 2.5 or higher based on the available data;
these patients were categorized as high risk.Otherwise,
the IPSS score was not calculated (n 5 6). If the only
blast percentage available was that found in peripheral
blood, that value was used to calculate the IPSS score.
Cytogenetics
Cytogenetic risk stratification was based on cate-
gories identified by the IPSS scoring system [5].
Good-risk cytogenetics included normal chromo-
somes and, when present as the sole karyotypic abnor-
mality, deletion of 5q or 20q or loss of the Y
chromosome. Poor-risk cytogenetics included any
chromosome 7 abnormality or complex karyotypes
with 3 or more abnormalities. Intermediate-risk cyto-
genetics included all other karyotypic findings.
Treatment History
The patients’ treatment histories were categorized
as active treatment, no active treatment (eg, only growth
factor or transfusion support), or treatment unknown.
Active treatments included hypomethylating agents
(azacitidine or decitabine), acutemyelogenous leukemia
(AML)-type cytarabine-based induction therapy, lenali-
domide/thalidomide, miscellaneous therapy (including
antithymocyte globulin [ATG], cyclosporine (CsA),
hydroxyurea, amifostine, etc.), or unknown. The ther-
apy given just prior to HSCT was the treatment noted
for analysis.
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having persistent disease or complete remission
(CR). Patients with normalization of blood counts,
resolution of cytogenetic abnormalities, and normal
marrow blast percentage, even with mild unilineage
dysplasia, were classified as CR. Patients with ongoing
dysplasia or progression of WHO classification, per-
sistence of their original cytogenetic abnormality, or
whose pre-HSCT cytogenetic results were unknown
were classified as residual MDS-treated.
Data and Statistical Methods
Patient outcomes post-HSCT were prospectively
collected. Factors considered in the analyses were:
IPSS score and WHO category at diagnosis, blast
percentage at diagnosis and time of transplant (\5%
versus $5%), cytogenetic abnormalities at diagnosis
and time of transplant, disease status at transplant
(CR, MDS-untreated, persistent MDS-treated, acute
leukemia untreated, or residual leukemia-treated),
year of transplant, age at transplant, sex, recipient
CMV serostatus, donor type, conditioning regimen in-
tensity, and acute graft-versus-host disease (aGVHD)
as a time-dependent covariate.
Endpoints
Endpoints for analysis were TRM, relapse, DFS,
and OS. Engraftment status and the development of
aGVHD and chronic GVHD (cGVHD) were also as-
sessed.
Measures of engraftment included neutrophil
recovery to an absolute neutrophil count (ANC) of
0.5  109/L for 3 consecutive days and 7 days of un-
transfused platelet recovery .50  109/L. Diagnoses
of aGVHD and cGVHD were based on standard clin-
ical criteria with histopathologic confirmation where
possible. Diagnosis of relapse was based on hemato-
logic, morphologic, and cytogenetic evaluation.
OS and DFS were estimated by the Kaplan-Meier
method [6], with statistical comparison completed us-
ing the Log-Rank test and Cox regression for multiple
regression analysis [7]. Cumulative incidence estimates
of neutrophil engraftment, platelet recovery, relapse,
TRM and GVHD (treating nonevent deaths (or re-
lapse for TRM) as a competing risk) were calculated
[8]. The method of Fine and Gray [9] was used in mul-
tiple regression analysis for the competing risk end-
points.
Patient Characteristics
Patient, disease, and transplant characteristics are
described in Table 1. The median age at time of trans-
plant was 50 years (range: 18-69), with a slight male
predominance (60%). TheWHO subtype at diagnosis
was RA in 1 (1%), RCMD and RCMD-RS in 23
(27%), RAEB-1 in 22 (26%), RAEB-2 in 13 (16%),MDS-U in 14 (17%), CMML in 7 (8 %), MDS/
MPD unclassifiable in 3 (4%), and MDS-NOS in 1
(1%). Marrow cytogenetics at diagnosis were available
in 79 (94%) of patients, of whom 17 (21%) had normal
cytogenetics. According to the IPSS cytogenetic risk
categorization, 19 (23%) were good risk, 23 (27%)
were intermediate risk, 37 (44%) were high risk, and
5 (6%) were unknown. The IPSS scores at diagnosis
were low risk in 3 (4%), INT-1 in 29 (35%), INT-2
in 38 (45%), high risk in 8 (9%), and unknown in 6
(7%).
Before they underwent HSCT, 49 (58%) patients
received supportive care only, 17 (20%) received
AML-type cytarabine based induction, 5 (6%) received
hypomethylating agents, 4 (5%) received lenalido-
mide/thalidomide, and 9 (11%) receivedmiscellaneous
or unknown types of therapy.
At the time of HSCT, 5 (6%) patients were in CR,
50 (60%) had MDS-untreated, 23 (27%) had persis-
tent MDS-treated, 1 (1%) had progressed to AML-
untreated, and 5 (6%) had progressed and had
persistent leukemia-treated. At HSCT, 57 (68%) had
fewer than5%blasts,whereas 27 (32%)had$ 5%blasts.
Fifty-two (62%) patients received myeloablative
(MA) conditioning and 32 (38%) nonmyeloablative
(NMA) conditioning including fludarabine (Flu; 40
mg/m2  5 days, cyclophosphamide (Cy) 50 mg/kg
and low-dose (200 cGy) total body irradiation (TBI).
Twenty patients undergoing NMA conditioning also
received ATG (15 mg/kg twice a day for 3 days) per
protocol as they had not been exposed to multiagent
chemotherapy within the 3 months preceding HSCT.
Two patients received NMA conditioning because of
medical comorbidities; the others were either older
than 45 years (for unrelated donor [URD] or umbilical
cord blood [UCB]; 55 years for related donors) or had
extensive previous therapy. ForMA conditioning, 85%
receivedCy (60mg/kg for 2 days) plusTBI (165 cGY
8 [1320 cGy]). Forty-seven (56%) patients received re-
lated donor peripheral blood stem cell (PBSC) (n 5
42)/marrow grafts (n 5 5), 11 (13%) URD marrow,
and 26 (31%) UCB.Supportive Care
All patients received transfusions, infection pro-
phylaxis (including cytomegalovirus [CMV]/herpes
simplex virus (HSV), fungal, and bacterial), and
GVHD prophylaxis according to institutional guide-
lines. For GVHD prophylaxis, all patients received cy-
closporine (CsA), targeting trough levels.200 ng/mL
through day 1180, along with either a short course of
methotrexate for those receiving MA conditioning or
mycophenolate mofetil (MMF) through day 130 for
those receiving either UCB or NMA conditioning.
All patients, MA and NMA, received filgrastim 5 mg/
kg/day starting day 11 after transplantation and
Table 1. Patient and Transplant Characteristics
Factors
Myeloablative
Conditioning
Nonmyeloablative
Conditioning All Patients
N 52 32 84
Year at transplant
1995-2000 25 (48%) 1 (3%) 26 (31%)
2001-2007 27 (52%) 31 (97%) 58 (69%)
Age at transplant
Median (range) 46 (18-55) 58 (18-69) 50 (18-69)
Sex
Male 31 (60%) 19 (59%) 50 (60%)
Female 21 (40%) 13 (41%) 34 (40%)
Recipient CMV status
Negative 25 (48%) 12 (38%) 37 (44%)
Positive 27 (52%) 20 (62%) 47 (56%)
Donor type
Related: 39 (85%) 8 (25%) 47 (56%)
PBSC: 42
Marrow: 5
Unrelated marrow 8 (15%) 3 (9%) 11 (13%)
Unrelated cord blood 5 (10%) 21 (66%) 26 (31%)
WHO MDS diagnosis
RA 0 1 (3%) 1 (1%)
RCMD/RCMD-RS 12 (23%) 11 (34%) 23 (27%)
RAEB-1 14 (27%) 8 (25%) 22 (26%)
RAEB-2 11 (21%) 2 (6%) 13 (16%)
MDS-U/CMML/other 15 (29%) 10 (31%) 25 (30%)
Cytogenetics at diagnosis:
Good risk: (normal,
5q-, 20q-, -Y)
13 (25%) 6 (19%) 19 (23%)
Intermediate risk:
(Trisomy 8, 2
abnormalities,
miscellaneous)
11 ( 21%) 12 (38%) 23 (27%)
Poor risk: (complex,
abnormalities of 7)
26 (50%) 11 (34%) 37 (44%)
Unknown 2 (4%) 3 (9%) 5 (6%)
Blast percentage at
diagnosis
<5% 26 (50%) 18 (56%) 44 (52%)
5-10% 18 (35%) 11 (34%) 29 (35%)
11-20% 8 (15%) 2 (6%) 10 (12%)
Unknown 0 1 (3%) 1 (1%)
IPSS at diagnosis
Low 2 (4%) 1 (3%) 3 (4%)
INT-1 15 (29%) 14 (44%) 29 (35%)
INT-2 26 (50%) 12 (38%) 38 (45%)
High 7 (13%) 1 (3%) 8 (9%)
Unknown 2 (4%) 4 (3%) 6 (7%)
Active therapy prior to
transplant
None 34 (65%) 15 (47%) 49 (58%)
Hypomethylating agents 2 (4%) 3 (9%) 5 (6%)
AML induction 9 (17%) 8 (25%) 17 (20%)
Lenalidomide/
thalidomide
0 4 (13%) 4 (5%)
Other 7 (14 %) 2 (6%) 9 (11%)
Disease status at transplant
Complete remission 4 (8%) 1 (3%) 5 (6%)
MDS untreated 35 (67%) 15 (47%) 50 (60%)
Persistent MDS,
treated
9 (17%) 14 (44%) 23 (27%)
AML, untreated 0 1 (3%) 1 (1%)
AML PR, treated 4 (8%) 1 (3%) 5 (6%)
Blast percentage at
transplant
CR 4 (8%) 1 (3%) 5 (6%)
<5% 30 (58%) 22 (69%) 52 (62%)
5-10% 11 (21%) 6 (19%) 17 (20%)
11-20% 7 (13%) 2 (6%) 9 (11%)
Unknown 0 1 (3%) 1 (1%)
Follow-up among survivors
Median (range) in years 3.1 (0.8-10.5) 1.8 (0.8-4.1) 2.4 (0.8-10.5)
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2 consecutive days.RESULTS
Engraftment and GVHD
The cumulative incidence of neutrophil engraft-
ment at day 142 was 88% (80%-96%, 95% confi-
dence interval [CI]) with median engraftment of 17
days (range: 2-33). Platelet recovery to .50,000/mL
at day 142 was 56% (43%-69%, 95% CI) with a me-
dian time to engraftment of 33 days (range: 0-125).
Overall rates of graft failure were 12% (4%-20%,
95%CI), with the majority in cord blood grafts. There
was no significant difference in time to neutrophil
engraftment between MA or NMA conditioning or
with different graft sources (data not shown). Platelet
engraftment was slightly delayed with cord blood ver-
sus related HCT (median 59 vs. 26 days) (P 5 .08).
The day 1100 overall cumulative incidence of
grade II-IV aGVHD was 43% (36%-50%, 95% CI)
and only 14% (9%-19%, 95% CI) for grade III-IV
GVHD. By conditioning intensity, there was no statis-
tical difference in rates of aGVHD grades II-IV with
MA (37% [23%-51%, 95% CI]) and NMA (53%
[33%-73%, 95% CI]) (P 5 .11) conditioning. Addi-
tionally by graft source, there were no significant dif-
ference in rates of aGVHD grade II-IV with related
40% (25%-55%, 95% CI), unrelated 36% (8%-64%,
95% CI), and UCB 50% (30%-70%, 95% CI) trans-
plants (P5 .38). The cumulative incidence of cGVHD
at 1 year was 15% (10%-20%, 95% CI).
Survival
After a median follow-up of 2.4 years (range: 0.8-
10.5 years), 54 patients had died at a median of 9
months (range: 7 days to 9.2 years). The probability
of OS at 1 and 5 years was 48% (38%-58%, 95% CI)
and 31% (20%-42%, 95% CI), respectively. The find-
ing of a low blast percentage at the time of transplant
was associated with a trend toward improved out-
comes. Patients in CR or with \5% blasts before
HSCT had an OS at 1 year of 53% (40%-66%, 95%
CI) compared to 35% (17%-43%, 95% CI) in those
with 5%-20% blasts (P5 .14). In multivariate analysis,
considering the variables of year of transplant,
age, CMV status, donor type, WHO at diagnosis,RA indicates refractory anemia; RCMD, refractory cytopenias with
multilineage dysplasia; RCMD-RS, refractory cytopenias with multiline-
age dysplasia-ringed sideroblasts; RAEB, refractory anemia with excess
blasts; MDS-U, myelodysplastic syndrome unclassifiable; AML, acute my-
elogenous leukemia; CMML, chronic myelomonocytic leukemia; other
includes MDS/MPD (myelodysplastic syndrome/myeloproliferative dis-
ease) unclassifiable and MDS-NOS, myelodysplastic syndrome not oth-
erwise specified; PR, partial remission.
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Figure 1. Cumulative incidence of relapse at 1 year. CR1\5% blasts
18% (18%-28%, 95% CI) versus 35% (16%-54%, 95% CI) in those with
5%-20% blasts.
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plant, conditioning intensity, sex, and time-dependent
aGVHD, patients with grade II-IV aGVHD had im-
proved OS with a relative risk (RR) of 0.5 (0.3-1.0,
95% CI) (P 5 .04). Patients with MDS-other (includ-
ing CMML, MDS/MPD, MDS-U, and MDS-NOS),
had a statistically significant improved OS compared
to patients with RAEB-2 with an RR of 0.4 (0.2-1.0,
95% CI) (P 5 .04). The intensity of the conditoning
regimen had no significant impact on OS.
TRM
The cumulative incidence of TRM at 1 year was
39% (28%-50%, 95% CI). Of these 35 nonrelapse
deaths, 16 were because of GVHD, 14 infection, 3
organ failure, 1 hemorrhage, and 1 veno-occlusive
disease (VOD). TRM at 1 year was similar based on
conditioning regimen (MA 42% [28%-56%, 95%
CI] and NMA 34% [17%-51%, 95% CI]) (P 5 .66),
as well as stem cell source (related 47% [32%-62%,
95% CI], unrelated marrow 64% [33%-95%, 95%
CI], and UCB 31% [13%-47%, 95% CI]) (P 5 .53).
TRM was similar in patients who achieved a CR or
\5% blasts prior to HSCT either with or without
prior treatment (40% [21%-59%, 95% CI] versus
33% [16%-50%, 95% CI]), respectively (P 5 .66).
Relapse
Twenty patients relapsed after HSCT at a median
of 100 days (range: 21-1097 days), leading to a 1- and
5-year cumulative incidence of relapse of 23% (12%-
32%, 95% CI) and 25% (15%-35%, 95% CI), respec-
tively. Nineteen of these 20 patients died. As shown in
Table 2, patients with a blast percentage \5% at
HSCT had a lower incidence of relapse at 1 year ofTable 2. Relapse/Treatment-Related Mortality (TRM)Analysis
Factors N Number of relapses
Total 84 20
Percentage blast
at HCT
CR + <5% 57 11
5%-20% 26 9
Conditioning
Myeloablative 52 9
Nonmyeloablative 32 11
Donor source
Related 47 6
Unrelated marrow 11 2
UCB 26 7
Among CR + <5% Blasts at HCT
Myeloablative 34 4
Nonmyeloablative 23 7
No prior therapy 30 7
Prior therapy 25 4
Among $ 5% blasts at HCT
Myeloablative 18 5
Nonmyeloablative 8 4
HCT indicates hematopoietic cell transplant; CR, complete remission; TRM,
interval.18% (8%-28%, 95% CI) compared with 35% (16%-
54%, 95% CI) in those with 5%-20% blasts (P 5
.07) (Figure 1). Patients who underwent MA condi-
tioning relapsed less frequently with a 1-year incidence
of 16% (6%-26%, 95% CI) compared with 35%
(18%-52%, 95% CI) in those who underwent NMA
conditioning (P5 .06). MA patients also relapsed later
with a median time to relapse of 4.8 versus 2.2 months
(NMA) (Figure 2). In patients in CR or with \5%
blasts who had MA conditioning, the incidence of re-
lapse at 1 year was much lower at 9% (0%-18%,
95% CI) compared to 31% (11%-51%, 95% CI) in
those receiving NMA conditioning (P 5 .04) (Fig-
ure 3). Interestingly, in the population of patients
with $5% blasts at transplantation, the incidence of
relapse with MA conditioning was also 22% lower at
28% (8%-48%, 95% CI) versus 50% (18%-82%,
95% CI) in the NMA group, but the difference was
not significant (P 5 .33).
For thepatientswhowere inCRorhad\5%blast at
the time of HCT, we analyzed whether prior treatment1-Year Relapse (95% CI) 1-Year TRM (95% CI) P-Value
23% (12%-32%) 39% (28%-50%)
18% (8%-28%) 37% (24%-50%) .07 (relapse)
35% (16%-54%) 46% (26%-66%) .61 (TRM)
16% (6%-26%) 42% (28%-56%) .06 (relapse)
35% (18%-52%) 34% (17%-51%) .66 (TRM)
13% (4%-22%) 47% (32%-62%) .34 (relapse)
18% (0%-38%) 64% (33%-95%) .53 (TRM)
28% (10%-46%) 31% (13%-47%)
9% (0%-18%) 38% (22%-54%) .04 (relapse)
31% (11%-51%) 35% (15%-55%) .99 (TRM)
20% (6%-34%) 33% (16%-50%) .82 (relapse)
16% (2%-30%) 40% (21%-59%) .66 (TRM)
28% (8%-48%) 50% (26%-74%) .33 (relapse)
50% (18%-82%) 38% (7%-69%) .67 TRM
treatment-related mortality; UCB, umbilical cord blood; CI, confidence
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Figure 2. Cumulative incidence of relapse at 1 year in patients receiv-
ing MA conditioning was 16% (6%-26%,95% CI) versus 35% (18%-52%,
95% CI) in NMA conditioning.
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difference in 1-year incidence of relapse was seen with
16% (2%-30%, 95% CI) in treated versus 20% (6%-
34%, 95%CI) in untreated patients (P5 .82). In all pa-
tients, late relapse was uncommon: only 1 patient re-
lapsed later than 1 year after HSCT.DFS
DFS at 1 and 5 years was 38% (28%-48%, 95%
CI) and 29% (19%-39%, 95% CI) respectively (Table
3). The blast percentage at HSCT was the only factor
associated with a trend toward improved 1-year DFS
in both univariate and multivariate analysis (CR,
80% [45%-100%, 95% CI];\5% blasts, 42% [29%-
55%, 95% CI]; and 5%-20% blasts 19% [4%-34%,
95% CI]) (P 5 .12) (Figure 4). DFS at 1 year was sim-
ilar using either MA (42% [29%-55%, 95% CI]) or
NMA conditioning (31% [15% 47%, 95% CI]) (P 5
.46). Interestingly, in patients in CR or with \5%
blasts at HSCT, whose rates of relapse were signifi-
cantly improved with MA conditioning, DFS was sim-
ilar after either type of conditioning intensity (data not
shown). There was a trend toward improved DFS in
NMA patients who received therapy prior to trans-
plant 54% (25%-76%, 95% CI) for treated versus
10% (1%-36%, 95% CI) for untreated (P 5 .06), but
no such trend was noted with MA conditioning (33%Years
p = .04
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Figure 3. Cumulative incidence of relapse at 1 year in patients with CR
or\5% blasts at HCTreceiving MA conditioning was 9% (0%-18%, 95%
CI) versus 31% (11%-51%, 95% CI) in NMA conditioning.[10%-59%, 95% CI] with prior treatment versus
65% [40%-82%, 95%CI]) for untreated (P5 .14). In-
terestingly, in MA patients, the trend was the opposite
with those pretreated showing a trend towards worse
DFS.
The donor source did not have an impact on 1-year
DFS (related donor HCT, 40% [26%-54%, 95% CI];
URD, 27% [1%-53%, 95% CI]; and UCB, 38%
[19%-57%, 95% CI]) (P 5 .72).
Multivariate analysis (Table 4) confirmed that out-
comes were similar following bothMA andNMA con-
ditioning, but demonstrated a trend toward improved
DFS in those patients undergoing HSCT with\5%
blasts.DISCUSSION
Numerous controversies still exist regarding trans-
plantation in MDS: timing of transplantation, disease
burden at transplant, conditioning intensity, the need
for pretransplant therapy, and stem cell source. Al-
though only prospective randomized studies can defin-
itively answer a number of these questions, data from
our retrospective review of a relatively large popula-
tion of MDS patients will add to the information avail-
able to help guide clinical decision making regarding
transplantation.
The data presented in this study support previous
reports showing that MDS patients who have a low
disease burden at the time of HSCT have superior sur-
vival and the lowest relapse rates [1,10]. Although
achieving a CR in MDS is uncommon, the patients
in our study who were in CR at the time of HSCT
had the best 1-year DFS (80%). We observed im-
proved DFS and lower relapse rates in those patients
with either a CR or \5% blasts compared to those
with 5% to 20% blasts. Thus, based on our data and
IPSS risk stratification, we suggest proceeding to allo-
geneic transplantation (MA or NMA) in INT-2/high-
risk patients with \5% marrow blasts to optimize
relapse rates and DFS.
Over the past decade, new therapies have become
available for MDS patients including azacitidine, dec-
itabine, and lenalidomide, changing the landscape of
MDS therapy. With a goal to initiate HSCT with
\5% blasts, for those patients with an increased dis-
ease burden, the decision on pre-HSCT therapy mo-
dality depends upon patients’ performance status as
well as the pace of their disease and time to desired re-
sponse. Although outpatient treatment with azaciti-
dine or decitabine has lesser toxicity and decreased
periods of aplasia, the time to response is longer, and
thus for those patients where urgent responses are
needed, AML-type induction therapy may be the
most appropriate. Our data also suggest that the expo-
sure to prior therapy, if needed to reach the\5% blast
Table 3. DFS: Univariate Analysis
Factors N 1-Year Survival (95% CI) 5-Year Survival (95% CI) P-Value
Total 84 38% (28%-48%) 29% (19%-39%)
WHO MDS diagnosis .62
RCMD/RCMD-RS 23 30% (11%-49%) 15% (0%-68%)
RAEB-1 22 32% (12%-52%) 27% (8%-46%)
RAEB-2 13 38% (12%-64%) 38% (12%-64%)
MDS-other 26 49% (29%-69%) 35% (15%-45%)
IPSS at diagnosis .49
Low 3 67% (13%-100%) 67% (13%-100%)
INT-1 29 41% (23%-59%) 36% (28%-44%)
INT-2 38 31% (16%-46%) 19% (4%-34%)
High 8 38% (4%-72%) NE
Donor type .72
Related 47 40% (26%-54%) 31% (17%-45%)
PBSC/marrow
Unrelated marrow 11 27% (1%-53%) 18% (0%-41%)
Unrelated cord blood 26 38% (19%-57%) 33% (14%-52%)
Conditioning .46
Myeloablative 52 42% (29%-55%) 31% (18%-44%)
Nonmyeloablative 32 31% (15%-47%) 27% (11%-43%)
Cytogenetics at HCT .53
Normal or 20q- alone 25 47% (27%-67%) 38% (15%-61%)
Complex/abnormality of 7 29 38% (20%-56%) 27% (9%-45%)
Two abnormalities/
Trisomy 8/misc
21 33% (13%-53%) 24% (6%-42%)
Disease status
at HCT
.31
CR 5 80% (45%-100%) 80% (45%-100%)
MDS untreated 50 38% (25%-51%) 27% (14%-40%)
Persistent MDS, treated 23 35% (15%-55%) 29% (9%-49%)
AML, untreated
and PR treated
6 17% (0%-47%) NE
Percentage blast
at HCT
.14
CR+ <5% 57 45% (32%-58%) 31% (17%-45%)
5%-20% 26 19% (4%-34%) 19% (4%-34%)
CI indicates confidence interval; PR, partial remission; CR, complete remission; HCT, hematopoietic cell transplant; AML, acute myelogenous leukemia;
DFS, disease-free suvival; RA, refractory anemia; RCMD, refractory cytopenias with multilineage dysplasia; RCMD-RS, refractory cytopenias with multi-
lineage dysplasia-ringed sideroblasts; RAEB, refractory anemiawith excess blasts; MDS-U, myelodysplastic syndrome unclassifiable; CMML, chronic mye-
lomonocytic leukemia; other includes MDS/MPD (myelodysplastic syndrome/myeloproliferative disease) unclassifiable and MDS-NOS, myelodysplastic
syndrome not otherwise specified; PR, partial remission.
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TRM after transplant. Although these data need to
be interpreted with caution, we suggest that blast per-
centage at HSCT is the most important characteristic
predicting outcome and pretransplant therapy may
lead to improved DFS if successful in reaching theYears
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Figure 4. DFS at 1 year for those entering HCT in CR was 80% (45%-
100%, 95% CI), with\5% blasts was 42% (29%-55%, 95% CI), and with
5%-20% blasts was19% (4%-34%, 95% CI) P 5 .12.\5% blast percentage prior to HSCT, particularly
for NMA patients.
The impact of conditioning intensity on disease
control remains controversial, with some reports sug-
gesting that MA conditioning offers improved disease
control [11], but often at the expense of increased
TRM [12-14], whereas others report equivalence with
NMA techniques [15-17]. In the current analysis,
patients receivingMAconditioninghad lower risk of re-
lapse, particularly those inCRorwith\5%blasts.This
finding contrasts with those published by Scott et al.
[18], in which they found no difference in relapse rates
in patients with pre-HSCT disease control (defined as
CR with \5% blasts) between those who received
either MA or NMA conditioning. This discrepancy
highlights the importance of both disease burden at
HSCT and conditioning intensity. Interestingly, in
our analysis of patients with $5% blasts at transplant,
MA conditioning nonsignificantly reduced relapse
rates, suggesting that disease burden at time of trans-
plant is themost important disease status characteristic,
Table 4. DFS: Multivariate Analysis
Factor
Relative Risk
of Relapse or Death (95% CI) P
WHO classification at Diagnosis
RCMD/RCMD-RS 1.0
RAEB-1 0.7 (0.4-1.5) .42
RAEB-2 0.9 (0.4-2.1) .77
MDS-other 0.7 (0.3-1.3) .25
Cytogenetic abnormalities at
HCT 1.0
Normal Or 20q-alone 1.0 (0.6-2.0) .91
Complex/abnormality of 7 1.1 (0.5-2.1) .86
Two abnormalities/trisomy 8/misc
Percentage blast at HCT
Normal + <5% 1.0
5%-20% 1.6 (0.9-2.9) .12
Conditioning regimen
Myeloablative 1.0
Nonmyeloablative 1.3 (0.8-2.4) .31
DFS indicates disease-free survival; RA, refractory anemia; RCMD, re-
fractory cytopenias with multilineage dysplasia; RCMD-RS, refractory
cytopenias with multilineage dysplasia-ringed sideroblasts; RAEB, refrac-
tory anemia with excess blasts; MDS-U, myelodysplastic syndrome un-
classifiable; CMML, chronic myelomonocytic leukemia; other includes
MDS/MPD (myelodysplastic syndrome/myeloproliferative disease) un-
classifiable and MDS-NOS, myelodysplastic syndrome not otherwise
specified; PR, partial remission.
The following variables were considered in the regression model: year of
transplant, age at transplant, recipient CMV serostatus, donor type,
WHO classification, cytogenetics, percent blasts at transplant, condi-
tioning, gender, and acute graft-versus-host disease as a time-dependent
covariate.
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come increased pre-HSCT disease burden. Although
relapse rates among patients who received MA condi-
tioning, particularly those in CR or with\5% blasts,
were superior to those who received NMA condition-
ing, DFS, OS, and TRMwere equivalent. The findings
of similar DFS in the setting of improved relapse rates
and similar TRM reflect the need to improve both the
safety and antineoplastic potency of HSCT. Addition-
ally, the equivalent TRM between the NMA and MA
conditioning arms are interesting, and, in contrast to
some but not all reports [12-14], particularly when ex-
amining lateTRM(out to1 year) as in thecurrent series.
Our TRM for NMA conditioning was slightly higher
than other reported data. High TRM could be because
of a patient population with increased comorbidities
and using detailed pre-HSCTcomorbidity index scores
may be important predictors ofTRM[19]. In summary,
with respect to conditioning intensity, our data suggest
that MA conditioning should be preferred, when possi-
ble, based on patient performance status, age, andmed-
ical comorbidities. If such comorbidities preclude MA
conditioning, NMA conditioning is a reasonable alter-
native in those patients achieving a blast count\5%.
In this report, we also found that alternative donor
sources, including both URD and UCB grafts, re-
sulted in outcomes similar to matched sibling donors
following either MA or NMA conditioning. This
needs to be confirmed in larger, prospective studies.However, our results suggest that when sibling donors
are not available, cord blood transplants have the
potential to broaden the HSCT options for nearly all
patients with MDS.
In conclusion, our data suggests that marrow blasts
\5% at HSCT is the major predictor for improved
DFS and superior relapse rates and treatment required
to obtain that goal is advised particularly for patients
requiring NMA conditioning. Additional studies to
further clarify the impact of pretransplant therapy
and conditioning intensity, and to reduce both TRM
and relapse are still needed to enhance the success of
allografting for MDS.ACKNOWLEDGMENTS
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